



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/799,941	03/11/2004	Martha G. Welch	19240.477 US2	8041

56949 7590 07/21/2010  
WilmerHale/Columbia University  
399 PARK AVENUE  
NEW YORK, NY 10022

EXAMINER
----------

KOSAR, ANDREW D

ART UNIT	PAPER NUMBER
----------	--------------

1654

NOTIFICATION DATE	DELIVERY MODE
-------------------	---------------

07/21/2010

ELECTRONIC

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

teresa.carvalho@wilmerhale.com  
whipusptopairs@wilmerhale.com



Continuation of Substance of Interview including description of the general nature of what was discussed: Discussed amendments to the claims which would place the application in condition for allowance. Claim 26, being amended to inflammatory bowel disease, and new claim 32, drawn to treating primary biliary cirrhosis, would be allowable, finding sufficient enablement in the specification as filed. All remaining claims would be cancelled and the restriction would be withdrawn only to the extent 26 and 'new' claim 32 would be rejoined. The examiner indicated that Hollander (attached) would have formed the basis of the obviousness rejection, similar to that which was previously set forth, however it was published 1/03. Applicant's representative requested time to consult with the client/foreign associate. In the interview of 7/17/10, the examiner indicated that dependent claims from 26 and 32 would be entered and that 'inflammatory' would replace 'irritable' in claim 26, as it is the exemplified embodiment of the specification and appeared to be a typographical error, as irritable bowel disease is not a 'real' condition, but rather inflammatory bowel disease or irritable bowel syndrome. To the examiner, it was clear from the specification examples that 'inflammatory' was the correct term. Agreement was reached on allowable subject matter in an interview of 7/17/10.